ONCO
Onconetix, Inc.
Set alert
0.56 USD -0.02 -4.27%
0.5211 Day range 0.5849
0.399 52-week range 189.50
- YTD
- -99.28%
- 1 year
- -99.70%
- Open
- 0.543
- Prev close
- 0.586
- Mkt cap
- 3.30M
- Vol
- 1.19M
- Avg vol
- 3.76M
- EPS
- 310.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5211
- High
- 0.5849
- Forward P/E
- -0.41
- Beta
- 3.73
- Short ratio
- 0.45
- Inst. own
- 7.86%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.23
- 200-d avg
- 4.94
- 1y target
- 0.00
Key statistics
- Market cap
- 2.89M
- Enterprise value
- 21.96M
- Trailing P/E
- 0.00
- Forward P/E
- -0.41
- PEG ratio
- 0.00
- Price / sales
- 1.98
- Price / book
- 0.00
- EPS (TTM)
- -87.25
- Beta
- 3.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.46M
- Revenue growth
- 0.00%
- Free cash flow
- -6.06M
- Total cash
- 930.54K
- Total debt
- 15.28M
- Return on equity
- 0.00%
- Shares outstanding
- 8.29M
- Short % of float
- 0.72%
- 50-day average
- 2.23
- 200-day average
- 4.94
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ONCO Revenue — quarterly 17.12K
ONCO Net income — quarterly -2.87M
ONCO EPS — quarterly -1.28
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 9, 2024 | Sep 1, 2024 | 0.00 | -2.24 | — | — |
| Aug 29, 2024 | Jun 1, 2024 | 0.00 | -9.20 | — | — |
| May 20, 2024 | Mar 1, 2024 | 0.00 | -6.40 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 13, 2023 | Maxim Group | down | Buy | Hold |
| Apr 26, 2023 | HC Wainwright & Co. | main | — | Buy |
| Feb 1, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Dec 9, 2022 | HC Wainwright & Co. | init | — | Buy |
| Dec 8, 2022 | Maxim Group | init | — | Buy |
About Onconetix, Inc.
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- onconetix.gcs-web.com
News
- Onconetix Announces Realbotix Rolls Out Humanoid Robot Platform Echo
- Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Onconetix Announces 1-For-10 Reverse Stock Split Effective On November 6, 2026
- Onconetix Announces Reverse Stock Split
- Onconetix Makes Additional Advance Of $500K To Realbotix Under Strategic Bridge Financing Facility
- Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
- Realbotix Announces Additional Draw under Bridge Loan from Onconetix
Your note
Sign in to keep a note on ONCO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CINCINNATI CORNERSTONE INVESTORS BWV I LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 22, 2022 | 0 |
| GARFIELD JON M | Chief Financial Officer | Stock Award(Grant) | May 8, 2023 | 100,000 |
| HENDERSON ERIN | Officer | Stock Award(Grant) | May 8, 2023 | 174,752 |
| HERNANDEZ JOSEPH | Chief Executive Officer | Stock Award(Grant) | May 8, 2023 | 2,800,350 |
| JEREMIC VUK | Director | Stock Award(Grant) | May 30, 2023 | 6,360 |
| RAMDEEN TIMOTHY R. | Director | Stock Award(Grant) | May 30, 2023 | 6,360 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Zurcher Kantonalbank (Zurich Cantonalbank) | 6.78% | 562,691 | 196.38K | Sep 29, 2024 |
| American Financial Group Inc. | 0.43% | 36,023 | 12.57K | Sep 29, 2024 |
| UBS Group AG | 0.16% | 12,982 | 4.53K | Sep 29, 2024 |
| Bank of America Corporation | 0.07% | 5,466 | 1.91K | Sep 29, 2024 |
| Fifth Third Bancorp | 0.03% | 2,404 | 838 | Sep 29, 2024 |
| Blackrock Inc. | 0.02% | 1,338 | 466 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.05% | 4,038 | 1.41K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.02% | 1,837 | 641 | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 1,822 | 635 | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 166 | 57 | Oct 30, 2024 |